Dr Reddy’s Laboratories failed to cheer the market despite June quarter net profit doubling. Analysts see concern over the US business and pressure on operating performance as key drags. These concerns have prompted traders to build bearish bets on the stock. Chandan Taparia, derivative analyst at Motilal Oswal, said the weakness could continue and the stock could drift down to Rs 3,950.
Budget over, bulls back faster, higher, stronger
The NSE Nifty rose 428.75 points, or 1.76%, to close at a record of 24,834.85. The index hit a lifetime high of 24,861.15 during the